Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds

US11932845B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11932845-B2
Application numberUS-201314405390-A
CountryUS
Kind codeB2
Filing dateJun 3, 2013
Priority dateJun 4, 2012
Publication dateMar 19, 2024
Grant dateMar 19, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention provides non-naturally occurring microbial organisms having a 4-hydroxybutyrate, 1,4-butanediol, or other product pathway and being capable of producing 4-hydroxybutyrate, 1,4-butanediol, or other product, wherein the microbial organism comprises one or more genetic modifications. The invention additionally provides methods of producing 4-hydroxybutyrate, 1,4-butanediol, or other product or related products using the microbial organisms.

First claim

Opening claim text (preview).

What is claimed is: 1. A non-naturally occurring microbial organism, said microbial organism having a 4-hydroxybutyrate pathway and being capable of producing 4-hydroxybutyrate, wherein said microbial organism comprises a genetic modification that increases expression of a gamma-butyrolactone esterase relative to the microbial organism in the absence of the genetic modification to increase expression of a gamma-butyrolactone esterase, wherein the gamma-butyrolactone esterase converts gamma-butyrolactone to 4-hydroxybutyrate and decreases production of gamma-butyrolactone relative to the microbial organism in the absence of the genetic modification to increase expression of a gamma-butyrolactone esterase, wherein the gamma-butyrolactone esterase is expressed in a sufficient amount to produce 4-hydroxybutyrate, and wherein the microbial organism comprises a genetic modification that decreases expression of an alcohol dehydrogenase relative to the microbial organism in the absence of the genetic modification to decrease expression of an alcohol dehydrogenase. 2. The microbial organism of claim 1 , wherein said microbial organism further comprises a genetic modification selected from: (A) a genetic modification that increases expression of phosphoenolpyruvate carboxylase relative to the microbial organism in the absence of the genetic modification; (B) a genetic modification that increases expression of alpha-ketoglutarate dehydrogenase relative to the microbial organism in the absence of the genetic modification; (C) a genetic modification that increases expression of a non-phosphotransferase (PTS) glucose uptake system relative to the microbial organism in the absence of the genetic modification; (D) a genetic modification that decreases expression of succinyl-CoA synthetase relative to the microbial organism in the absence of the genetic modification; (E) a genetic modification that decreases expression of an acyl coenzyme A thioesterase relative to the microbial organism in the absence of the genetic modification; (F) a genetic modification that decreases expression of a non-energy-producing NADH dehydrogenase relative to the microbial organism in the absence of the genetic modification; (G) a genetic modification that decreases expression of a cytochrome oxidase relative to the microbial organism in the absence of the genetic modification; and (H) a combination of two or more, three or more, four or more, five or more, six or all of the genetic modifications of parts (A)-(G). 3. The microbial organism of claim 1 , wherein said microbial organism further comprises a 4-hydroxybutyryl-CoA pathway. 4. The microbial organism of claim 1 , wherein said microbial organism further comprises a 1,4-butanediol pathway. 5. The microbial organism of claim 1 , further comprising a genetic modification selected from: (i) a genetic modification that increases expression of pyruvate dehydrogenase relative to the microbial organism in the absence of the genetic modification; (ii) a genetic modification that decreases expression of an aerobic respiratory control regulatory system relative to the microbial organism in the absence of the genetic modification; (iii) a genetic modification that increases expression of an NADH insensitive citrate synthase relative to the microbial organism in the absence of the genetic modification; (iv) a genetic modification that decreases expression of malate dehydrogenase relative to the microbial organism in the absence of the genetic modification; (v) a genetic modification that decreases expression of lactate dehydrogenase relative to the microbial organism in the absence of the genetic modification; (vi) a genetic modification that decreases expression of pyruvate formate lyase relative to the microbial organism in the absence of the genetic modification; and (vii) a combination of two or more, three or more, four or more, five or all of the genetic modifications of parts (i)-(vi). 6. The microbial organism of claim 2 , wherein: (I) the microbial organism of part (A), (B) or (C) has decreased production of ethanol, acetate, pyruvate or alanine, or a combination thereof, relative to the microbial organism in the absence of said genetic modification; (J) the microbial organism of part (B) has decreased production of glutamate relative to the microbial organism in the absence of said genetic modification; (K) the microbial organism of part (C) has a genetic modification comprising increased expression of a permease, glucokinase, or a glucose facilitator, or a combination thereof relative to the microbial organism in the absence of said genetic modification; (L) the microbial organism of part (D) has increased production of 4-hydroxybutyrate relative to the microbial organism in the absence of said genetic modification; (M) the microbial organism of part (E) has decreased production of gamma-butyrolactone relative to the microbial organism in the absence of said genetic modification; (N) the microbial organism of part (E) has a genetic modification comprising at least two genetic modifications that decrease expression of at least two acyl coenzyme A thioesterases relative to the microbial organism in the absence of said genetic modification; (O) the microbial organism of part (F) has suppressed depletion of the NADH pool or increased energy efficiency in the microbial organism, or a combination thereof, relative to the microbial organism in the absence of said genetic modification; (P) the microbial organism of part (G) has increased energy efficiency relative to the microbial organism in the absence of said genetic modification; or (Q) the microbial organism of part (G) has increased tolerance to a range of oxygen concentrations relative to the microbial organism in the absence of said genetic modification. 7. A method for producing 4-hydroxybutyrate, comprising culturing the non-naturally occurring microbial organism of claim 1 under conditions and for a sufficient period of time to produce 4-hydroxybutyrate. 8. A method for producing 1,4-butanediol, comprising culturing the non-naturally occurring microbial organism of claim 4 under conditions and for a sufficient period of time to produce 1,4-butanediol. 9. A method for producing isolated or purified 4-hydroxybutyrate or 1,4-butanediol, comprising culturing the non-naturally occurring microbial organism of claim 4 under conditions and for a sufficient period of time to produce 4-hydroxybutyrate or 1,4-butanediol, and isolating or purifying the 4-hydroxybutyrate or 1,4-butanediol. 10. The method of claim 9 , wherein the isolating or purifying comprises distillation. 11. The microbial organism of claim 1 , wherein the microbial organism has decreased backflux from a downstream product of the 4-hydroxybutyrate pathway relative to the microbial organism in the absence of said genetic modification to decrease expression of an alcohol dehydrogenase.

Assignees

Inventors

Classifications

  • C12N1/20Primary

    Bacteria; Culture media therefor · CPC title

  • 1,4-Butanediol; 1,3-Butanediol; 1,2-Butanediol; 2,3-Butanediol · CPC title

  • Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups · CPC title

  • Compounds containing ester groups, e.g. oxyalkylated monocarboxylic acids · CPC title

  • aliphatic · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11932845B2 cover?
The invention provides non-naturally occurring microbial organisms having a 4-hydroxybutyrate, 1,4-butanediol, or other product pathway and being capable of producing 4-hydroxybutyrate, 1,4-butanediol, or other product, wherein the microbial organism comprises one or more genetic modifications. The invention additionally provides methods of producing 4-hydroxybutyrate, 1,4-butanediol, or other …
Who is the assignee on this patent?
Genomatica Inc
What technology area does this patent fall under?
Primary CPC classification C12N1/20. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).